Objective To develop and validate Clinical Diversity In Meta-analyses (CDIM), a new tool for
assessing clinical diversity between trials in meta-analyses of interventions. Study design …

Purpose Corticosteroids are now recommended for patients with severe COVID-19 including
those with COVID-related ARDS. This has generated renewed interest regarding whether …

Purpose We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients
with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, …

Background In the early phase of the pandemic, some guidelines recommended the use of
corticosteroids for critically ill patients with COVID‐19, whereas others recommended against …

IMPORTANCE Dexamethasone 6 mg daily is recommended for up to 10 days in patients
with severe and critical COVID-19, but a higher dose may benefit those with more severe …

Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given
daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe …

The currently recommended dose of dexamethasone for patients with severe or critical
COVID-19 is 6 mg per day (mg/d) regardless of patient features and variation. However, patients …

Background Days alive without life support (DAWOLS) and similar outcomes that seek to
summarise mortality and non-mortality experiences are increasingly used in critical care …

Background The coronavirus disease 2019 (COVID‐19) pandemic has resulted in millions
of deaths and overburdened healthcare systems worldwide. Systemic low‐dose …

To the Editor The COVID STEROID 2 trial1 assessed the effect of 12 mg/d vs 6 mg/d of
dexamethasone on days alive without life support at 28 days, 28-day mortality, and 90-day …